Turning Point Therapeutics News

Chicago Capital Management LLC Takes $10.17 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Chicago Capital Management LLC acquired a new stake in shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the 2nd quarter, Holdings Channel.com reports. The institutional inves

Financial News LiveOct 10, 2022 10:51 ET

Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Versor Investments LP bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Se

Financial News LiveOct 9, 2022 12:21 ET

Brinker Capital Investments LLC Buys Shares of 3,167 Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Brinker Capital Investments LLC bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing w

Defense WorldOct 9, 2022 04:51 ET

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 7.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm

Defense WorldOct 9, 2022 04:12 ET

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages

Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analys

Defense WorldSep 19, 2022 02:22 ET

ProShare Advisors LLC Sells 3,250 Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

ProShare Advisors LLC reduced its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 19.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 13,760 shares of th

Defense WorldSep 5, 2022 04:11 ET

Turning Point Therapeutics (NASDAQ:TPTX) Sees Strong Trading Volume

Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) shares saw unusually-high trading volume on Tuesday . Approximately 50,472 shares were traded during trading, a decline of 94% from the pr

Defense WorldAug 18, 2022 05:02 ET

News On Turning Point Therapeutics Inc. (TPTX) Now Under BMY

News On Turning Point Therapeutics Inc. (TPTX) Now Under BMY

Dow JonesAug 17, 2022 17:09 ET

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Dow JonesAug 17, 2022 08:31 ET

Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio

Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio NEW YORK--(BUSINESS WIRE)--August 17, 2022-- Bristol Myers Squibb (NYSE:BMY) announce

Dow JonesAug 17, 2022 08:31 ET

Turning Point Therapeutics (NASDAQ:TPTX) Sees Unusually-High Trading Volume

Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) saw strong trading volume on Tuesday . 50,472 shares changed hands during mid-day trading, a decline of 94% from the previous ses

Financial News LiveAug 16, 2022 13:01 ET

Bristol Myers' $4.1B Turning Point Acquisition Gets Clearance in US, Germany, Set to Close

Bristol Myers Squibb's (NYSE:BMY) $4.1B acquisition of Turning Point Therapeutics (NASDAQ:TPTX) received antitrust clearance in the U.S. and Germany. New York-based Bristol Myers said that while the w

Seeking AlphaAug 16, 2022 07:48 ET

Bristol Myers, Turning Point See Deal Closing Aug. 17 >BMY

Bristol Myers, Turning Point See Deal Closing Aug. 17 >BMY

Dow JonesAug 16, 2022 07:00 ET

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance From Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the rec

BusinessWireAug 16, 2022 07:00 ET

Express News | Bristol Myers Squibb, Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and C

Moomoo 24/7Aug 16, 2022 06:59 ET

IndexIQ Advisors LLC Purchases New Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

IndexIQ Advisors LLC purchased a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the first quarter, according to the company in its most recent filing with the Securities

Defense WorldAug 12, 2022 06:21 ET

SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) – SVB Leerink reduced their Q3 2022 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on

Defense WorldAug 12, 2022 01:21 ET

JMP Securities Remains a Hold on Turning Point Therapeutics (TPTX)

JMP Securities analyst Silvan Tuerkcan maintained a Hold rating on Turning Point Therapeutics (TPTX – Research Report) today. The company's shares closed yesterday at $75.04. Tuerkcan covers the Healt

TipRanksAug 10, 2022 00:45 ET

Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results

Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) announced its quarterly earnings data on Monday. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate

Financial News LiveAug 9, 2022 08:51 ET

Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M misses by $2.15M

Turning Point Therapeutics press release (NASDAQ:TPTX): Q2 GAAP EPS of -$2.48 misses by $0.78. Revenue of $0.12M (-97.7% Y/Y) misses by $2.15M.

Seeking AlphaAug 8, 2022 16:48 ET